Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Lopinavir ritonavir AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
177 results
  • Clinical trials for coronavirus disease 2019: What is being evaluated and what is not. [Journal Article]
    Ann Thorac Med. 2020 Apr-Jun; 15(2):49-51.Arabi YM, Asseri A, … Al Moamary MS
  • Since the report of the first case of coronavirus disease 2019 (COVID-19) in China in late December 2019, there have been 204 610 cases worldwide as of 18 March, 2020. As part of the response to this outbreak, there has been an impressive amount of research undertaken to better characterize the disease and to evaluate therapeutic options. By March 12, 2020, there are more than 382 studies registe…
  • The association between treatment with heparin and survival in patients with Covid-19. [Journal Article]
    J Thromb Thrombolysis. 2020 May 31 [Online ahead of print]Ayerbe L, Risco C, Ayis S
  • This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temper…
  • Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? [Journal Article]
    J Microbiol Immunol Infect. 2020 May 25 [Online ahead of print]Owa AB, Owa OT
  • Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. Till date, no drug has been approved for the treatment of this infection. A number of medications have been proposed and there are ongoing clinical trials around the world to find a suitable treatment. A recent randomised control trial compared lopinavir/ritonavir with standard care amon…
  • Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. [Letter]
    J Infect. 2020 May 27 [Online ahead of print]Klement-Frutos E, Burrel S, … Boutolleau D
  • No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS…
  • Emerging pharmacotherapies for COVID-19. [Review]
    Biomed Pharmacother. 2020 May 14; 128:110267.Salvi R, Patankar P
  • Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 d…
  • Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. [Review]
    Pharmacol Ther. 2020 May 26 [Online ahead of print]Liu T, Luo S, … Shi GP
  • The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2118 on-going clinical trials underway, but to d…
  • Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. [Review]
    Infect Dis Ther. 2020 May 27 [Online ahead of print]Fajgenbaum DC, Khor JS, … Pierson SK
  • The emergence of SARS-CoV-2/2019 novel coronavirus (COVID-19) has created a global pandemic with no approved treatments or vaccines. Many treatments have already been administered to COVID-19 patients but have not been systematically evaluated. We performed a systematic literature review to identify all treatments reported to be administered to COVID-19 patients and to assess time to clinically m…
  • Can Zn Be a Critical Element in COVID-19 Treatment? [Review]
    Biol Trace Elem Res. 2020 May 26 [Online ahead of print]Rahman MT, Idid SZ
  • The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale a…
  • Battling COVID-19: using old weapons for a new enemy. [Review]
    Trop Dis Travel Med Vaccines. 2020; 6:6.Kumar R, Gupta N, … Wig N
  • Coronavirus disease-19 (COVID-19) has reached pandemic proportions. Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and ev…
  • A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19. [Journal Article]
    Clin Pharmacol Ther. 2020 May 23 [Online ahead of print]Peck RW, Weiner D, … Powell JR
  • The SARS-CoV-2 pandemic and associated COVID-19 disease are straining healthcare systems around the world with large numbers of patients becoming ill in a very short period of time, overwhelming healthcare systems in many countries. Several drugs are being repurposed into clinical trials in COVID-19 patients, ranging from drugs already well established in other diseases, such as chloroquine/hydro…
  • Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. [Journal Article]
    mBio. 2020 05 22; 11(3)Park SJ, Yu KM, … Choi YK
  • Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-C…
  • Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS? [Review]
    Br J Pharmacol. 2020 May 22 [Online ahead of print]Curtin N, Bányai K, … Bai P
  • Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFα levels (key interleukins in SA…
  • Potential specific therapies in COVID-19. [Review]
    Ther Adv Respir Dis. 2020 Jan-Dec; 14:1753466620926853.Gul MH, Htun ZM, … Khan A
  • COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated co…
  • A novel coronavirus (SARS-CoV-2) and COVID-19. [Journal Article]
    Cas Lek Cesk. 2020 Spring; 159(2):55-66.Trojánek M, Grebenyuk V, … Stejskal F
  • By the end of 2019 the first cases of severe pneumonia of unknown origin were reported in Wuhan, China. The causative agent was identified as a novel b-coronavirus SARS-CoV-2 and the disease was named COVID-19. Since the beginning of 2020, the infection has spread worldwide, which led the WHO to declare COVID-19 a public health emergency of international concern and to characterize the current si…
  • Psychopharmacology of COVID-19. [Review]
    Psychosomatics. 2020 May 18 [Online ahead of print]Bilbul M, Paparone P, … Ernst CL
  • CONCLUSIONS: Clinicians should be aware of the need to adjust existing psychotropics or avoid using certain medications in some COVID-19 patients. They should also be familiar with neuropsychiatric effects of medications being used to treat this disease. Further research is needed to identify strategies to manage psychiatric issues in this population.
New Search Next